Design and synthesis of piperazine-indole p38α MAP kinase inhibitors with improved pharmacokinetic profiles

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 828-831

  Tan, Xuefei ^a   Tester, Richland W ^a   Luedtke, Gregory R ^a   Chakravarty, Sarvajit ^a   Mavunkel, Babu J ^a   Perumattam, John J ^a   Lu, Qing ^a   Nashashibi, Imad ^a   Jung, Joon ^a   Hu, Jie ^a   Liclican, Albert ^a   Almirez, Ramona ^a   Tabora, Jocelyn ^a   Tran, Vinh ^a   Laney, Maureen ^a   Levy, Daniel E ^a   Dugar, Sundeep ^a  

^a SCIOS INC   (United States)

Author keywords

Inflammatory; Inhibitor; Kinase; MAP; p38

Indexed keywords

CARBENE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PIPERAZINE DERIVATIVE; SCIO 469; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 14; PIPERAZINE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DOG; DRUG EFFECTS; HAPLORHINI; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; SYNTHESIS;

ANIMALS; DOGS; DRUG DESIGN; HAPLORHINI; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 14; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; RATS;

EID: 74049110562     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.091     Document Type: Article

References (20)

1. Jarvis B., and Faulds D. Drugs 57 (1999) 945
2. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., Weaver A.L., Keystone E.C., Furst D.E., Mease P.J., Ruderman E.M., Horwitz D.A., Arkfeld D.G., Garrison L., Burge D.J., Blosch C.M., Lange M.L.M., McDonnell N.D., and Weinblatt M.E. Ann. Intern. Med. 130 (1999) 478
3. Choy E.H., and Panayi G.S.N. Eng. J. Med. 344 (2001) 907
4. Markham A., and Lamb H.M. Drugs 59 (2000) 1341
5. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNutly D., Blumenthal M.J., Heyes J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., and Young P.R. Nature 372 (1994) 739
6. Kumar S., Boehm J., and Lee J.C. Nat. Rev. Drug Disc. 2 (2003) 717
7. Saklatvala J. Curr. Opin. Pharmacol. 4 (2004) 372
8. Foster M.L., Halley F., and Souness J.E. Drug News Perspect. 13 (2000) 488
9. Pargellis C., and Regan J. Curr. Opin. Invest. Drugs 4 (2003) 566
10. Smith R.J. Drug Discovery Today 10 (2005) 1598
11. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold G.E. J. Pharmacol. Exp. Ther. 279 (1996) 1453
12. Kubota T., Miyagishima M., Alvarez R.J., Kormos R., Rosenblum W.D., Demetris A.J., Semigran M.J., Dec G.W., Holubkov R., McTiernan C.F., Mann D.L., Feldman A.M., and McNamara D.M. J. Heart Lung Transplant. 19 (2000) 819
13. Sticherling M. Drug Discovery Today: Disease Mech. 2 (2005) 275
14. http://www.accessmylibrary.com/article-1G1-70735265/scios-begin-phase-ib.html.
15. http://clinicaltrials.gov/ct2/show/NCT00089921.
16. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Dugar, S.; Lu, Q.; Liang, X. WO 2000/071535, 2000 ((d)-tartaric acid was used in the chiral resolution to obtain (2S,5R)-2,5-dimethyl-4-fluoro-benzyl piperazine tartaric salt).
17. Baroudy, B. M.; Clader, J. W.; Josien, H. B.; Mccombie, S. W.; Mckittrick, B. A.; Miller, M. W.; Neustadt, B. R.; Palani, A.; Smith, E. M.; Steensma, R.; Tagat, J. R.; Vice, S. F.; Laughlin, M. A.; Gilbert, E.; Labroli, M. A. WO 2000/066558, 2000.
18. (2R,5S)-Dimethyl-piperazine-1-carboxylic acid tert-butyl ester was synthesized using same procedure as for the synthesis of intermediate 5, except (l)-tartaric salt of chiral (2S,5R)-2,5-dimethyl-4-fluorobenzyl piperazine was used.
19. Mavunkel, B. J.; Perumattam, J. J.; Tan, X.; Luedtke, G. R.; Lu, Q.; Lim, D.; Kizer, D.; Dugar, S.; Chakravarty, S.; Xu, Y.-j.; Jung, J.; Liclican, A.; Levy, D. E.; Tabora, J. Bioorg. Med. Chem. Lett., in press. doi:10.1016/j.bmcl.2009.12.031.
20. The LPS/TNFα Human Whole Blood Assay was run as described in: Mavunkel, B.; Dugar, S.; Luedtke, G.; Tan, X.; McEnroe, G. US Patent 6,696,443, 2004.